It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
LONDON - Over the next 35 years, multidrug-resistant tuberculosis will kill 75 million people and could cost the global economy a cumulative £15 trillion - the equivalent of the European Union’s annual output, a UK parliamentary group said on Tuesday. If left untackled, the spread of drug-resistant TB superbugs threatens to shrink the world economy by 0.63 percent annually, the UK All Party Parliamentary Group on Global Tuberculosis (APPG TB) said, urging governments to do more to improve research and cooperation
The WHO said last year multidrug-resistant TB was at "crisis levels", with about 480,000 new cases in 2013. It is a manmade problem caused by regular TB patients given the wrong medicines or doses, or failing to complete their treatment, which is highly toxic and can take up two years.
CDC published a report outlining the top 18 drug-resistant threats to the United States. These threats were categorized based on level of concern: urgent, serious, and concerning.
Clostridium Difficile (CDIFF)
Carbapenem-Resistant Enterobacteriaceae (CRE)
Extended Spectrum Enterobacteriaceae (ESBL)
Vancomycin-Resistant Enterococcus (VRE)
Multidrug-Resistant Pseudomonas Aeruginosa
Drug-Resistant Non-Typhoidal Salmonella
Drug-Resistant Salmonella Serotype Typhi
Methicillin-Resistant Staphylococcus Aureus (MRSA)
Drug-Resistant Streptococcus Pneumoniae
Vancomycin-Resistant Staphylococcus Aureus
Erythromycin-Resistant Group A Streptococcus
Clindamycin-Resistant Group B Streptococcus
originally posted by: MentorsRiddle
I have recently read where they are working on a new anti-biotic that is considered a "super-antibiotic".
Biological Challenges to Post-Eradication
…vaccine-preventable viruses (e.g., polio and measles) are characterized by boom-and-bust epidemic cycles which exhibit extraordinary non-linear dynamics due to the complex population-level interactions that influence transmission.
Major biological challenges after eradication include:
….continuing and improving surveillance for the detection of vaccine-associated cases, recrudescence (outbreaks) of infection, new zoonotic transmissions, and the emergence of recombinant viral strains.
………Most notably, vaccine-associated paralytic poliomyelitis (VAPP) demonstrates how vaccine-associated cases of disease can occur even when disease due to wild-type virus is eliminated. Post-eradication strategies will require continual surveillance, more information about the duration of shedding and the persistence of the vaccine-derived virus in the environment, and continuing vaccine coverage even in areas where wild-type virus has been eradicated.
Viruses have extraordinary evolutionary strategies about which we have very little understanding. Continual surveillance and improved sampling methods are essential for tracking new genetic variants, particularly as more vaccines are introduced worldwide and rarer genotypes are selected for. The chance that new viruses could evolve underscores the need for continued development of improved vaccines and vaccine delivery systems.